281234-49-9

Basic information

• Product Name: 4'-FORMYL-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER
• Synonyms: SALOR-INT L480622-1EA;METHYL 4'-FORMYL[1,1'-BIPHENYL]-3-CARBOXYLATE;4'-FORMYL-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER;AKOS BAR-0327;Methyl 3-(4-formylphenyl)benzoate;4-[3-(Methoxycarbonyl)phenyl]benzaldehyde
• CAS NO: 281234-49-9
• Molecular Formula: C₁₅H₁₂O₃
• Molecular Weight: 240.25
• Mol File: 281234-49-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4'-FORMYL-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-FORMYL-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER(281234-49-9)
• EPA Substance Registry System: 4'-FORMYL-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER(281234-49-9)

Safety Data

• Hazardous Substances Data: 281234-49-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4'-FORMYL-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER is used as a synthetic intermediate for the development of non-steroidal Farnesoid X Receptor (FXR) agonists. These agonists are important in the treatment of various metabolic disorders, such as cholestasis, dyslipidemia, and non-alcoholic steatohepatitis, by modulating bile acid synthesis and regulating lipid and glucose homeostasis.
Used in Chemical Synthesis:
4'-FORMYL-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER serves as a key building block in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and specialty chemicals. Its aromatic structure and functional groups allow for further chemical modifications and reactions, making it a valuable starting material in the development of new molecules with potential applications in various industries.
Used in Research and Development:
4'-FORMYL-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER is also utilized in research and development settings to study its chemical properties, reactivity, and potential applications in different fields. Researchers can use 4'-FORMYL-BIPHENYL-3-CARBOXYLIC ACID METHYL ESTER to explore new synthetic routes, develop novel compounds, and investigate its potential as a pharmaceutical candidate or a precursor in the synthesis of other valuable molecules.

Upstream product

• 333-27-7 methyl trifluoromethanesulfonate 
• 222180-20-3 4'-formyl-biphenyl-3-carboxylic acid 
• 618-89-3 methyl 3-bromobenzoate 
• 67-56-1 methanol 
• 1122-91-4 4-bromo-benzaldehyde 
• 99769-19-4 [3-(methoxycarbonyl)phenyl]boronic acid 
• 87199-17-5 4-formylphenylboronic acid, 

Downstream Products

• 281232-91-5 3'-methoxycarbonyl-biphenyl-4-carboxylic acid 

Relevant articles and documents

Elucidation of Mechanism for Ligand Efficacy at Leukotriene B4Receptor 2 (BLT2)

G protein-coupled receptors (GPCRs) have always been important drug targets in the pharmaceutical industry. One major question for the current GPCR drug discovery is how drugs have distinct efficacies at the same GPCR target. Related to this question, we studied how different ligands can have disparate efficacies at Leukotriene B4 receptor (BLT2). By using molecular modeling studies, we predicted that Tyr2716.51 located at TM6 of BLT2 performs as a key trigger for its activation and verified the prediction by site-directed mutagenesis, chemotactic motility studies, which included a chemical derivative of agonist CAY10583. We further identified Asn2756.55 located at TM6 as a weak activation trigger in BLT2 and performed double mutation studies to confirm our computational results. Our results provide strong evidence for the exact mechanism of ligand efficacy at BLT2.

NOVEL BIPHENYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES COMPRISING THE SAME AS ACTIVE INGREDIENT

The present invention relates to a novel biphenyl derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising the same as an active ingredient, and methods for treating inflammatory disease or autoimmune diseases with the pharmaceutical composition. Novel biphenyl derivatives according to the present invention promote the phagocytosis of macrophages and inhibit the chemotaxis to exhibit excellent inflammation terminating and anti-inflammatory effects and thus can be effectively used as therapeutic agents for inflammatory diseases or autoimmune diseases.

Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists

A virtual screening procedure was applied to the discovery of structurally diverse non-steroidal Farnesoid X Receptor (FXR) agonists. From 117 compounds selected by virtual screening, a total of 47 compounds were found to be FXR agonists, with 34 of them showing activity below a concentration of 20 μM. 1H-Pyrazole[3,4-e][1,4]thiazepin-7-one-based hit compound 7 was chosen for hit-to-lead optimization. A large number of 1H-pyrazole[3,4-e][1,4]thiazepin-7- one derivatives was designed, synthesized, and evaluated by a cell-based luciferase transactivation assay for their agonistic activity against FXR. Most of them exhibited low micromolar range of potency and very high efficacy.

Design, synthesis, and structure-affinity relationships of novel series of sialosides as CD22-specific inhibitors

Sialosides incorporating substituted amides or amines at 9-position of sialic acid moiety have been synthesized and evaluated as CD22 inhibitors. Several derivatives exhibited inhibitory potency in sub- to low micromolar range (e. g., 80, 9d, 9g, and 9k s

NOVEL QUINOLINIUM SALTS AND DERIVATIVES

The present invention relates generally to the synthesis of novel quinolinium salts and derivative compounds. Such salts and compounds are useful for inhibiting the growth of cancer cells.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.